1 completed, 1 recruiting, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow telacebec: new trials by email Literature Review of telacebec trials Research Report on telacebec
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU) Telacebec - Buruli Ulcer | Phase 2 | Recruiting | Barwon Health | 200 | 2024-07-09 | 2026-06-30 |
| A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients Telacebec, COVID-19 Standard of care - COVID-19 Virus Infection | Phase 2 | Terminated | Qurient Co., Ltd. | 1 | 2021-07-29 | 2022-03-02 |
| A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203) Telacebec (Q203), Rifafour e-275 - Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB | Phase 2 | Completed | Qurient Co., Ltd. | 60 | 2018-07-23 | 2019-09-10 |
Buruli Ulcer (1) · COVID-19 (1) · Ulcer (1)
Qurient Co., Ltd. (2) · Barwon Health (1)
South Africa (2) · Australia (1)